Neovasc Inc.

Recent News

  • Neovasc Provides Corporate Update Following Clinical Data Release

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 20, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference ("TCT") held September 16-19 in Boston.Prof. Shmuel Banai, MD, Neovasc Medical Director and Head of Interventional Cardiology at the Tel Aviv Medical Center, Israel, presented new interim clinical data on the use of the Neovasc Reducer™ ("Reducer") in patients who have angina with non-obstructive coronary artery disease, so-called...

    2022-09-20 9:05 AM EDT
  • Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 16, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24, 2022.Neovasc's President and Chief Executive Officer, Fred Colen, will be presenting at 11:10 am BST / 6:10 am ET on September 23, 2022. Interested parties may view a live stream of Mr. Colen's presentation by registering on...

    2022-09-16 9:00 AM EDT
  • Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 15, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today commented on the Centers for Medicare and Medicaid Services ("CMS") development of new codes for the diagnosis and tracking of refractory angina. The new codes will be utilized in the current, 10th revision of the International Statistical Classification of Diseases and Related Health Problems Clinical Modification ("ICD-10-CM"). The latest update was published in the ICD-10-CM Tabular List of Diseases and Injuries...

    2022-09-15 9:05 AM EDT
  • Neovasc Announces Key Events at TCT 2022

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference ("TCT"), hosted by the Cardiovascular Research Foundation ("CRF"), taking place in person at the Boston Convention & Exhibition Center, September 16-19, 2022. Members of the Neovasc team will be available at booth 647 in the exhibit hall.New Investigational Data to be PresentedOn Monday, September...

    2022-09-08 9:05 AM EDT
  • Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 30, 2022) - Neovasc, Inc. (Neovasc or the Company) (NASDAQ: NVCN) (TSX: NVCN) today announced that its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022, in New York City. Neovasc's President and Chief Executive Officer, Fred Colen, will be presenting at 1:30 pm ET on Tuesday, September 13, 2022. A live webcast of the presentation can be accessed using the...

    2022-08-30 9:05 AM EDT
  • Neovasc Announces Second Quarter Financial Results and Provides Corporate Update

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 11, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the second quarter ended June 30, 2022.Recent HighlightsGenerated revenues of $818,000, a quarterly record and a year-over-year increase of 29% over the second quarter of 2021.Advanced enrollment in the COSIRA II trial with 40 patients enrolled and 21 patients randomized across 10 sites.COSIRA II protocol supplement was approved by the FDA, more than...

    2022-08-11 4:05 PM EDT
  • Neovasc to Report Second Quarter Financial Results on August 11, 2022

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on August 11, 2022.Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International)...

    2022-07-28 9:00 AM EDT
  • Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 26, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the United States Food and Drug Administration ("FDA") has approved a protocol supplement to the COSIRA-II Investigational Device Exemption ("IDE") Trial. The approval expands the number of patients eligible for treatment in the trial and adds two previously planned imaging sub-studies designed to provide insights into the safety and mechanism of action of the Neovasc Reducer™...

    2022-07-26 9:05 AM EDT